INTERVIEW: Cash-rich Mesoblast rolls into late-stage study of stem cells for spinal fusion
This article was originally published in Clinica
Executive Summary
Australian stem cell specialist Mesoblast is planning a Phase III study of its mesenchymal precursor cells (MPCs) in spinal fusion after reporting positive results in a Phase II study. The spinal fusion indication is the second-most advanced for the MPCs after heart failure – Mesoblast revealed plans to start a Phase III trial in heart failure just over a year ago (www.clinica.co.uk, 15 November 2011).